Supplementary Tables 1 - 4, Figures 1 - 2 from Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs
posted on 2023-03-31, 17:33authored byDenis L. Jardim, Kenneth R. Hess, Patricia LoRusso, Razelle Kurzrock, David S. Hong
PDF file - 309K, Supplemental table 1 - Drugs included in the analysis and their respective phase I trials. Supplemental table 2 - Drugs included in the analysis and their respective schedule and later trial leading to FDA approval. Supplemental table 3 - Agents and Phase I trials characteristics. Supplemental table 4 - Univariate analysis of the probability of adopting the RP2D plus or minus 20% according to phase I trials characteristics. Supplemental Figure 1 - Flow diagram of search results. Supplemental figure 2 - Analysis of the probability of adopting the RP2D in relation to continuous variables.